|
1.1 Biologie - Gènes
|
|
|
|
|
3. Prévention
|
|
|
|
3.1 Tabac
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
5. Traitements
|
|
|
Stem cell gene targeted to treat drug-resistant pancreatic cancer [FierceBiotech]
|
|
|
|
|
|
The
investigators developed antisense oligonucleotide (ASO) inhibitors that
targeted and blocked Msi-expressing cells, which arrested tumor growth
in animal models as well as in cancer cells obtained from patients. ASO
inhibitors work by selectively binding to messenger RNA from the chosen
disease-linked gene and inactivating it.
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.5.1.1 ASCO (général) - Industriels
|
|
|
|
5.5.13 ASCO (divers)
|
|
|
|
|
5.5.16 ASCO (médecine de précision)
|
|
|
|
5.5.2 ASCO (sein)
|
|
|
|
5.5.4 ASCO (immunothérapies)
|
|
|
|
|
Immune Modulation in Colorectal and Anal Cancers [ESMO]
|
|
|
|
|
|
PD-1
blockade alone or in combination with CTLA-4 inhibition in
microsatellite unstable colon cancer, MEK inhibition plus PD-L1 in
microsatellite stable colon cancer, and PD-1 blockade in anal squamous
cell cancer warrant further investigation.
|
|
|
|
|
|
|
5.9.3 EHA
|
|
|
|
6.10 Politiques
|
|
|
|
6.11 Patients
|
|
|
|
6.8 Communication
|
|
|
|
6.9 Controverses
|
|
|